Full-Time

Executive Director – Reblozyl Marketing Brand Lead

Deadline 8/31/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$239.1k - $289.7k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Summit, NJ, USA + 1 more

More locations: Princeton, NJ, USA

In Person

On-site in Madison, NJ or Princeton, NJ.

Bachelor's, MBA

Category
Growth & Marketing (1)
Required Skills
Data Analysis

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Requirements
  • Bachelor’s degree required; MBA or advanced degree preferred.
  • Minimum 15 years of experience in biopharmaceutical marketing, including senior leadership roles.
  • Proven track record leading large brands or portfolios in Oncology or specialty therapeutics.
  • Direct experience with product launches, lifecycle management, and late‑stage pipeline assets.
  • Demonstrated ability to operate effectively in matrixed, global organizations.
  • Strong strategic thinking, executive presence, and ability to influence at the most senior levels.
  • Experience navigating complex market access and reimbursement environments.
  • Experience spanning both U.S. commercialization and global brand strategy (preferred).
  • Prior leadership of hematology or lymphoma brands (preferred).
Responsibilities
  • Lead development and execution of the U.S. Reblozyl brand strategy across all approved and future indications.
  • Own brand performance, market growth, and achievement of commercial objectives.
  • Develop annual brand plans, operating plans, and resource allocation strategies aligned with business priorities.
  • Drive positioning, messaging, promotional strategy, customer engagement, and omnichannel execution.
  • Ensure disciplined execution against brand objectives, KPIs, and performance milestones.
  • Provide strategic marketing leadership for global Reblozyl commercialization, with a focus on:
  • Ex‑U.S. launch and expansion strategies
  • Lifecycle management planning
  • Indication sequencing and prioritization
  • Actively participate in Global Product Team (GPT) and related governance bodies, ensuring strong integration between global strategy and U.S. insights.
  • Partner with Global Commercial, Medical, and Development teams to shape long‑term brand vision, evidence strategies, and global value narratives.
  • Translate U.S. market learnings into global best practices and inform regional strategies.
  • Lead the Reblozyl cross-functional business team, aligning stakeholders across Marketing, Sales, Medical Affairs, Market Access, Patient Services, Analytics, Finance, Regulatory, Legal, and Commercial Operations.
  • Partner closely with Sales leadership to maximize field effectiveness, customer engagement, and commercial execution.
  • Serve as the senior marketing leader for Reblozyl in governance forums, POAs, business reviews, and leadership meetings.
  • Build, develop, and lead a high-performing marketing organization while fostering a culture of accountability, innovation, inclusion, and collaboration.
  • Recruit, coach, and develop talent, ensuring strong succession planning and organizational capability building.
  • Deliver strategic recommendations and business updates to senior Oncology and Commercial leadership while contributing to broader organizational priorities and enterprise initiatives
Desired Qualifications
  • Experience spanning both U.S. commercialization and global brand strategy (preferred)
  • Prior leadership of hematology or lymphoma brands (preferred)

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 earnings lifted revenue guidance to $49-$50 billion after a $12.97 billion quarter.
  • Eliquis growth improved to 20%-25% for 2026, easing near-term patent-cliff pressure.
  • Iberdomide's FDA decision lands August 17, 2026, potentially adding a first-in-class myeloma therapy.

What critics are saying

  • Eliquis launches generic on April 1, 2028, slicing BMS's biggest cash engine.
  • Opdivo loses core U.S. patent protection in 2028, inviting biosimilar and pricing attacks.
  • AstraZeneca merger talks, reported August 2, 2026, face FTC divestitures that can kill the deal.

What makes Bristol Myers Squibb unique

  • BMS still anchors oncology with Opdivo, Reblozyl, Breyanzi, and Opdualag driving 2026 growth.
  • BMS deployed Nvidia DGX SuperPOD in 2026, pairing drug discovery with compute-scale AI.
  • Houston's 2026 campus and $40 billion U.S. commitment lock manufacturing capacity domestically.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Aug 10th, 2026
Bristol Myers Squibb to build $2.3B Houston drug manufacturing campus

Bristol Myers Squibb will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its $40 billion US investment commitment over five years. The 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates. The campus will employ nearly 500 people in operations, production, engineering, quality control, and administration. Construction is expected to support roughly 2,000 workers through 2030 before operations fully launch. Texas Governor Greg Abbott announced Bristol Myers is eligible for a $4.89 million grant through the Texas Enterprise Fund. The company selected Houston after evaluating multiple markets, citing workforce availability in life sciences, incentives, and infrastructure proximity. Bristol Myers raised its full-year revenue forecast to approximately $49 billion to $50 billion earlier this year.

Yahoo Finance
Aug 7th, 2026
BMS claims pharma's most powerful supercomputer with Nvidia, beating Lilly and Roche

Bristol Myers Squibb announced an expanded partnership with Nvidia to build what it claims will be "the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences". BMS joins Eli Lilly and Roche in staking supercomputer superlative claims, though companies use different metrics to measure power. According to Nvidia, BMS' planned system will be the most advanced by operations per second, whilst others measure by GPU count or single system capacity. The companies are pursuing greater computing power to train larger models, run more complex experiments, and accelerate drug discovery. BMS has worked with Nvidia for nearly three years. The company previously used AI to overcome a plateau whilst searching for a clinical candidate for a sickle cell programme. Under the expanded deal, BMS will deploy Nvidia's DGX SuperPOD supercomputer, delivering up to ten times greater performance per megawatt than its predecessor.

Yahoo Finance
Aug 5th, 2026
Bristol Myers Squibb deploys Schrödinger's AI co-scientist Bunsen for drug discovery

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.

Yahoo Finance
Aug 3rd, 2026
AstraZeneca shares plunge 8%, wiping out $22B after Bristol Myers merger rumours

AstraZeneca and Bristol Myers Squibb have held initial discussions about a potential merger that would create a combined entity worth nearly $400 billion, according to reports citing people familiar with the matter. The market reaction was sharply negative, with AstraZeneca shares falling more than 8%, wiping out roughly $22 billion in market value, whilst Bristol Myers dropped almost 1.5%. The deal would strengthen AstraZeneca's cancer and cardiovascular drug portfolios, which accounted for 44% and 22% respectively of its $59 billion revenue last year. Bristol Myers faces upcoming patent losses for key drugs including immunotherapy Opdivo and blood thinner Eliquis. Analysts questioned the strategic rationale, noting AstraZeneca's recent success under CEO Pascal Soriot.

Merced Sun-Star
Aug 2nd, 2026
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports.

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports. By Reuters Reuters Updated August 2, 2026 4:05 PM Gift Article Aug 2 (Reuters) - UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion. The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialize soon, but could also be delayed or fall apart. Reuters could not immediately verify the report. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment. Last year, AstraZeneca unveiled plans for a direct U.S. listing, aiming to capitalize on stronger valuations in the U.S. market while remaining listed in London. STRONG GROWTH IN CANCER DRUGS AstraZeneca's share price has more than quadrupled during Pascal Soriot's 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK. Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth. Cancer treatments accounted for about $25 billion in 2025 sales, nearly half of the total, followed by cardiovascular, renal and metabolism treatments worth about $12 billion. Combining with Bristol Myers, whose shares are up around 44% over the last year, could draw attention from antitrust regulators. Oncology drugs accounted for over 40% of its overall sales in the first six months of 2026, and the two companies' cancer immunotherapies directly compete. "I would expect a Trump FTC to scrutinize the merger and if there are significant overlaps in certain drugs and late stage pipeline overlaps it would require meaningful divestitures," said antitrust lawyer Andre Barlow with DBM Law Group, referring to the U.S. Federal Trade Commission. Bristol Myers has been doing smaller deals to gain new drugs as it faces declining sales of older medicines, some of which will soon face generic competition. In 2019, Bristol Myers bought Celgene for about $80 billion, acquiring its flagship blood cancer drug Revlimid, which became Bristol's top-selling product. Revlimid has already lost patent protection and its current top sellers - cancer immunotherapy Opdivo and blood thinner Eliquis - could lose patent protection by 2028. Barlow noted that in the deal for Celgene, the Trump FTC required Celgene to sell psoriasis treatment Otezla, a major divestiture at $13.4 billion. "There is bipartisan support to scrutinize pharma deals so I would imagine that even the Trump FTC would ask the broader questions relating to bundling of products and a lack of future innovation, in addition to scrutinizing all direct overlaps," he said. Bristol raised its full-year revenue and profit forecast last week as strong sales of Eliquis and newer medicines pushed second-quarter results well past analysts' estimates. Its promising newer drugs and pipeline assets include an experimental blood thinner milvexian, anemia treatment Reblozyl and heart drug Camzyos. The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger U.S. rival Pfizer. Large pharma deals have been rare in recent years, in part due to concerns about antitrust and U.S. pressure to keep drug prices low. Besides Bristol and Celgene, AbbVie bought Allergan in 2020 and Takeda and Shire combined in 2019. (Reporting by Devika Nair in Bengaluru and Michael Erman in New Jersey; Additional reporting by Chris Sanders in Washington; Editing by Caroline Humer and Bill Berkrot) This story was originally published August 2, 2026 at 12:36 PM.